Cardiovascular
Hypertensive
0
Pipeline Programs↗
12
Active Trials↗
17
Companies Involved↗
Hypertensive is an early-stage landscape with 0 programs across 17 companies. The most active players are Novartis, Boehringer Ingelheim, AstraZeneca.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
173
clinical trials
Completed117 · 68%
Unknown status26 · 15%
Terminated10 · 6%
Withdrawn8 · 5%
Recruiting6 · 3%
Not yet recruiting5 · 3%
Other1 · 1%
Clinical Trials
Trial Activity
173 trials
Morning Versus Bedtime Dosing of Antihypertensive Medication
Recruiting·—·Phase 4·NCT05089448·300 enrolled
Short-Term Effects of Antihypertensive Drugs on Postural Balance and Fall Risk
Recruiting·—·N/A·NCT07099677·186 enrolled
Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study
Recruiting·—·N/A·NCT05498675·180 enrolled
Antihypertensive Drug Selection Based on Hemodynamic Phenotypes
Not yet recruiting·TThe Third Xiangya Hospital of Central South University·Phase 4·NCT07240909·240 enrolled
Immediate Fracture Risk After Antihypertensive Drug Initiation
Not yet recruiting·—·N/A·NCT06964217·10,000,000 enrolled
Page 1 of 12
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)